Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biosyent Inc (TSE:RX)
TSXV:RX
Holding TSE:RX?
Track your performance easily
RX Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$8.06 - C$11.49
Previous CloseC$11.06
Volume1.50K
Average Volume (3M)4.20K
Market Cap
C$130.48M
Enterprise ValueC$105.51M
Total Cash (Recent Filing)C$26.19M
Total Debt (Recent Filing)C$1.22M
Price to Earnings (P/E)18.1
Beta0.04
Next Earnings
Nov 20, 2024EPS Estimate
C$0.14Last Dividend Ex-Date
Sep 04, 2024Dividend Yield1.58%
Share Statistics
EPS (TTM)0.61
Shares Outstanding11,586,914
10 Day Avg. Volume1,765
30 Day Avg. Volume4,204
Standard Deviation0.08
R-Squared0.25
Alpha0.00717
Financial Highlights & Ratios
Price to Book (P/B)3.69
Price to Sales (P/S)4.04
Price to Cash Flow (P/CF)47.30
P/FCF Ratio50.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$11.75Price Target Upside6.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Biosyent News
PremiumCompany Announcements
BioSyent’s Q3 Sales Surge Amid Strategic Moves
PremiumCompany Announcements
BioSyent to Announce Q3 2024 Financial Results
PremiumPre-Earnings
Is RX a Buy, Before Earnings?
PremiumCompany Announcements
BioSyent Expands with Tibelia Asset Acquisition
PremiumCompany Announcements
BioSyent Maintains Dividend, Signals Growth
PremiumCompany Announcements
BioSyent Reports Record Sales and Strategic Growth in 2024PremiumPre-Earnings
Is RX a Buy, Before Earnings?Options Prices
Currently, No data available
---
Ownership Overview
25.03% Insiders
0.41% Mutual Funds
<0.01% Other Institutional Investors
74.56% Public Companies and
Individual Investors
RX FAQ
What was Biosyent Inc’s price range in the past 12 months?
Biosyent Inc lowest stock price was C$8.06 and its highest was C$11.49 in the past 12 months.
What is Biosyent Inc’s market cap?
Currently, no data Available
When is Biosyent Inc’s upcoming earnings report date?
Biosyent Inc’s upcoming earnings report date is Nov 20, 2024 which is 2 days ago.
How were Biosyent Inc’s earnings last quarter?
Biosyent Inc released its earnings results on Aug 26, 2024. The company reported C$0.13 earnings per share for the quarter, the consensus estimate of C$0.13 by C$0.
Is Biosyent Inc overvalued?
According to Wall Street analysts Biosyent Inc’s price is currently Undervalued.
Does Biosyent Inc pay dividends?
Biosyent Inc pays a Quarterly dividend of C$0.04 which represents an annual dividend yield of 1.58%. See more information on Biosyent Inc dividends here
What is Biosyent Inc’s EPS estimate?
Biosyent Inc’s EPS estimate is C$0.14.
How many shares outstanding does Biosyent Inc have?
Biosyent Inc has 11,797,395 shares outstanding.
What happened to Biosyent Inc’s price movement after its last earnings report?
Biosyent Inc reported an EPS of C$0.13 in its last earnings report, expectations of C$0.13. Following the earnings report the stock price went up 3.835%.
Which hedge fund is a major shareholder of Biosyent Inc?
Currently, no hedge funds are holding shares in TSE:RX
---
Biosyent Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$11.75 (6.24% Upside)
C$11.75 (6.24% Upside)
Insider Transactions
Sold Shares
Worth C$5.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.90%
12-Months-Change
Fundamentals
Return on Equity
20.88%
Trailing 12-Months
Asset Growth
4.97%
Trailing 12-Months
Company Description
Biosyent Inc
Biosyent Inc is a specialty pharmaceutical company engaged in developing pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. The company through its subsidiaries sources acquires or in-licenses pharmaceutical products and markets the products. Geographically all the activities are functioned through the region of Canada.
---
RX Stock 12 Month Forecast
Average Price Target
C$11.75
▲(6.24% Upside)
Technical Analysis
Best Analysts Covering RX
1 Year
1 Year Success Rate
5/5 ratings generated profit
1 Year Average Return
+20.52%
reiterated a buy rating 2 months ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +20.52% per trade.
---